Abstract
Background The Cyprus Biobank collects biosamples, medical and lifestyle information with the aim of reaching 16,500 Cypriots aged ≥18-years, by year 2027, as part of a multitasked EU funded project. Volunteers are both from the general population and from disease cohorts of focused research projects, who amongst others will contribute to canvas the architecture of the Cyprus human genome and study the healthy and morbid anatomy of Cypriots. The Cyprus Biobank is a research infrastructure pillar of the biobank.cy Center of Excellence in Biobanking and Biomedical Research.
Methods Within 3-years (November 2019-October 2022), 1348 participants of the general population who represent a subset of the Cyprus Biobank recruited individuals, were enrolled in the pilot study. The study did not include individuals from separate disease-specific cohorts. Extensive information was collected from each participant, including biochemistry, complete blood count, physiological, anthropometric, socio-demographic, diet, and lifestyle characteristics. Prevalent health conditions along with medication use and family history were recorded, including 58 biomarkers based on blood and urine samples. With a systematic recruitment campaign, the Biobank is continuously increasing the number of individuals in the general population cohort and is developing separate disease cohorts of the Cypriot population.
Results The pilot study enrolled 579 men and 769 women, aged between 18-85 years (median 48-years). The enrollment takes 40 minutes on average, including the collection of biological samples and phenotypic information. More than half (n=733, 55%) of the participants are educated to college level or above. Statistically significant differences were found between men and women regarding their education level (p<0.001), marital status (p=0.01) and employment status (p<0.001) but not their age (p=0.29). The most prevalent medical conditions recorded are hypertension (17.2%), osteoporosis (6.9%) and diabetes (6.0%).
Conclusions The Cyprus biobanking pilot study has successfully collected extensive baseline information from enrolled participants. The Biobank will comprise a rich data resource used to examine the major risk factors leading to public health burdens and develop strategies for disease prevention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The biobank.cy pilot study was supported by CY-Biobank, an EU Horizon 2020 Research and Innovation Programme under Grant Agreement no. 857122.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted from the Cyprus National Bioethics Committee, code ΕΕΒΚ/EΠ/2020/04
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Different parts of the text were updated. A sample size calculation was added. Some figures and/or tables were merged to avoid repetitions and extra figures were added for clarity (timeline of biobanking and data/sample retrieval & Geographical distribution of the 1348 participants of the pilot study). Extra information was also added on Table 5 which includes medical conditions and medication use.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author, upon a reasonable request.
